- Home
- LPTX vs NCNA Comparison
LPTX vs NCNA Comparison
Compare LPTX & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- NCNA
- Stock Information
- Founded
- LPTX 2011
- NCNA 1997
- Country
- LPTX United States
- NCNA United Kingdom
- Employees
- LPTX N/A
- NCNA N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- NCNA Health Care
- Exchange
- LPTX Nasdaq
- NCNA Nasdaq
- Market Cap
- LPTX 14.7M
- NCNA 15.4M
- IPO Year
- LPTX N/A
- NCNA 2017
- Fundamental
- Price
- LPTX $0.31
- NCNA $4.47
- Analyst Decision
- LPTX Hold
- NCNA Buy
- Analyst Count
- LPTX 1
- NCNA 2
- Target Price
- LPTX N/A
- NCNA $25.00
- AVG Volume (30 Days)
- LPTX 661.1K
- NCNA 187.0M
- Earning Date
- LPTX 08-19-2025
- NCNA 08-18-2025
- Dividend Yield
- LPTX N/A
- NCNA N/A
- EPS Growth
- LPTX N/A
- NCNA N/A
- EPS
- LPTX N/A
- NCNA N/A
- Revenue
- LPTX N/A
- NCNA N/A
- Revenue This Year
- LPTX N/A
- NCNA N/A
- Revenue Next Year
- LPTX N/A
- NCNA N/A
- P/E Ratio
- LPTX N/A
- NCNA N/A
- Revenue Growth
- LPTX N/A
- NCNA N/A
- 52 Week Low
- LPTX $0.22
- NCNA $0.03
- 52 Week High
- LPTX $4.79
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- LPTX 43.86
- NCNA 30.91
- Support Level
- LPTX $0.30
- NCNA $7.06
- Resistance Level
- LPTX $0.37
- NCNA $10.00
- Average True Range (ATR)
- LPTX 0.03
- NCNA 1.44
- MACD
- LPTX -0.00
- NCNA 0.07
- Stochastic Oscillator
- LPTX 28.53
- NCNA 3.94
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.